JP2012509321A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509321A5
JP2012509321A5 JP2011537428A JP2011537428A JP2012509321A5 JP 2012509321 A5 JP2012509321 A5 JP 2012509321A5 JP 2011537428 A JP2011537428 A JP 2011537428A JP 2011537428 A JP2011537428 A JP 2011537428A JP 2012509321 A5 JP2012509321 A5 JP 2012509321A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
ray powder
disintegrant
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011537428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509321A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/006235 external-priority patent/WO2010059239A2/en
Publication of JP2012509321A publication Critical patent/JP2012509321A/ja
Publication of JP2012509321A5 publication Critical patent/JP2012509321A5/ja
Pending legal-status Critical Current

Links

JP2011537428A 2008-11-21 2009-11-20 癌および他の疾患または障害の処置のための、４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの乳酸塩およびその薬学的組成物 Pending JP2012509321A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19988808P 2008-11-21 2008-11-21
US61/199,888 2008-11-21
US21039809P 2009-03-17 2009-03-17
US61/210,398 2009-03-17
PCT/US2009/006235 WO2010059239A2 (en) 2008-11-21 2009-11-20 Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014193355A Division JP2015017116A (ja) 2008-11-21 2014-09-24 癌および他の疾患または障害の処置のための、４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの乳酸塩およびその薬学的組成物

Publications (2)

Publication Number Publication Date
JP2012509321A JP2012509321A (ja) 2012-04-19
JP2012509321A5 true JP2012509321A5 (enExample) 2012-12-27

Family

ID=41508688

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011537428A Pending JP2012509321A (ja) 2008-11-21 2009-11-20 癌および他の疾患または障害の処置のための、４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの乳酸塩およびその薬学的組成物
JP2014193355A Pending JP2015017116A (ja) 2008-11-21 2014-09-24 癌および他の疾患または障害の処置のための、４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの乳酸塩およびその薬学的組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014193355A Pending JP2015017116A (ja) 2008-11-21 2014-09-24 癌および他の疾患または障害の処置のための、４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの乳酸塩およびその薬学的組成物

Country Status (4)

Country Link
US (1) US20100273808A1 (enExample)
EP (1) EP2370417A2 (enExample)
JP (2) JP2012509321A (enExample)
WO (1) WO2010059239A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
CR20170071A (es) 2009-06-29 2017-03-28 Agios Pharmaceuticals Inc Compuestos terapeuticos y composiciones
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
ME03074B (me) 2011-05-03 2019-01-20 Agios Pharmaceuticals Inc Akтivatori piruvat kinaze za upotrebu u terapiji
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
CN103058959B (zh) * 2013-01-04 2014-09-10 华东理工大学 一种n-(2-(4-甲基哌嗪-1-基)-5-甲酰苯基)酰胺类化合物及其应用
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20170007661A1 (en) * 2014-03-14 2017-01-12 Agios Pharmaceuticals, Inc Pharmaceutical compositions of therapeutically active compounds
PH12021551647A1 (en) * 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
MA44392B1 (fr) 2015-06-11 2023-10-31 Agios Pharmaceuticals Inc Procédés d'utilisation d'activateurs de la pyruvate kinase
ES2897959T3 (es) 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
KR20250126877A (ko) 2015-10-15 2025-08-25 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3195702A1 (en) 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Process of reworking

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2083693C (en) 1990-05-25 2002-01-01 Alfred Edward Ringwood Abrasive compact of cubic boron nitride and method of making same
US5101609A (en) 1991-07-15 1992-04-07 Eastman Kodak Company Cigarette package inspection indexing wheel
JP2753911B2 (ja) * 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
JPH05230044A (ja) * 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形
JP3532988B2 (ja) * 1995-02-22 2004-05-31 アベンティス ファーマ株式会社 ピレタニドの新規な結晶多形およびその製造方法
AU719392B2 (en) * 1996-10-01 2000-05-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
JP3011904B2 (ja) * 1997-06-10 2000-02-21 明久 井上 金属ガラスの製造方法および装置
ES2356886T3 (es) * 1998-03-31 2011-04-14 Kyowa Hakko Kirin Co., Ltd. Compuestos heterocíclicos nitrogenados.
AU2001293208A1 (en) * 2000-08-18 2002-03-04 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
US6956039B2 (en) * 2000-08-18 2005-10-18 Millennium Pharmaceuticals, Inc. Nitrogenous heterocylic compounds
EP2277877A1 (en) 2000-08-18 2011-01-26 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
DE60144284D1 (de) * 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US20040259881A1 (en) * 2001-02-02 2004-12-23 Anjali Pandey Nitrogenous heterocyclic compounds
AU2002254152A1 (en) * 2001-03-08 2002-09-24 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
US7058169B2 (en) * 2003-08-27 2006-06-06 D.B. Zwirn Finance, Llc Skill based chat function in a communication system
US7456189B2 (en) * 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
WO2005047244A2 (en) * 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
CA2586688A1 (en) * 2004-11-08 2006-05-18 New River Pharmaceuticals Inc. Synergistic effects of combined administration of mirtazapine and a stimulant compound
EP2395000A1 (en) * 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
JP2008526827A (ja) * 2005-01-07 2008-07-24 ファイザー・プロダクツ・インク ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタエンの速崩壊性投与形態
JP2009502804A (ja) * 2005-07-20 2009-01-29 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの新規な結晶形
DE102005042784A1 (de) 2005-07-26 2007-02-01 Bosch Rexroth Aktiengesellschaft Ventilanordnung und Kühlvorrichtung

Similar Documents

Publication Publication Date Title
JP2012509321A5 (enExample)
AU2021204278B2 (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
AU2021200202B2 (en) Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
JP2009534373A (ja) 新しい結晶形態のラミブジン
JP2012255038A (ja) 異常な細胞増殖の治療用のピリミジン誘導体
CN103562183B (zh) 奥米沙班的苯甲酸盐
KR20240093547A (ko) 리나프라잔 글루레이트의 메실레이트 염의 다형체
CN106854164A (zh) 沙库比曲氨丁三醇盐的一种新晶型及其制备方法和用途
EP2943454A1 (en) Tapentadol maleate and crystalline forms thereof
JP2021501771A (ja) 三環系ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤の結晶性塩
JP2026503096A (ja) リナプラザングルレート（ｌｉｎａｐｒａｚａｎ ｇｌｕｒａｔｅ）のマレイン酸塩の多形
KR20170023003A (ko) 5-클로로-ｎ-({(5ｓ)-2-옥소-3-[4-(5,6-디하이드로-4h-[1,2,4]트리아진-1-일)페닐]-1,3-옥사졸리딘-5-일}메틸)티오펜-2-카르복사미드 메탄설폰산염의 신규 결정형 및 이를 포함하는 약학 조성물
HK40112789A (zh) 结晶反丁烯二酸盐
JP2025186544A (ja) 三環式誘導体化合物の結晶形及びその製造方法並びにそれを含む薬学的組成物